The global breast cancer liquid biopsy market size is expected to reach USD 1.7 billion by 2030, expandingat a CAGR of 22.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth. With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment.
Breast Cancer Liquid Biopsy Market Report Highlights
- In 2021, the circulating tumor cells segment held a dominant revenue share owing to the effectiveness and precision offered by CTCs in the detection of cancer
- The early detection segment is projected to grow at the fastest CAGR over the forecast period, owing to the increasing adoption of liquid biopsy in early diagnosis of cancer and the rising need to provide effective treatment
- Treatment selection was the highest revenue-generating segment in 2021 owing to the availability of a high number of products that aid treatment selection
- Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing prevalence, improving healthcare infrastructure, and growing population
Gain deeper insights on the market and receive your free copy with TOC now @: Breast Cancer Liquid Biopsy Market Report
There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.
A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.
Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics’s subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.
For More Details or Sample Copy please visit link @: https://www.grandviewresearch.com/industry-analysis/breast-cancer-liquid-biopsy-market-report/request/rs1
List of Key Players of Breast Cancer Liquid Biopsy Market
- The Menarini Group
- NeoGenomics Laboratories.
- Hoffmann-La Roche Ltd.
- Myriad Genetics, Inc.
- QIAGEN
- Biocept, Inc.
- Sysmex Corporation
- Fluxion Biosciences, Inc.
- Epic Sciences, Inc.
- Thermo Fisher Scientific Inc.
Research Methodology
We employ a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecasts possible. We utilize a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our market estimates and forecasts are derived through simulation models. A unique model is created and customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously.
For Customized reports or Special Pricing please visit @: https://www.grandviewresearch.com/checkout/select-license/breast-cancer-liquid-biopsy-market-report
Segmented the global breast cancer liquid biopsy market based on circulating biomarkers, application, and region:
Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country - Wise Market Estimation Using Bottom - Up Approach
1.7 Global Market: Cagr Calculation
1.8 Research Assumptions
1.9 List Of Secondary Sources
1.10 List Of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Breast Cancer Liquid Biopsy Market Variables, Trends, & Scope
3.1 Breast Cancer Liquid Biopsy Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook - In Vitro Diagnostics (Ivd) Market
3.2 Penetration And Growth Prospect Mapping
3.3 Market Dynamics
3.4 Market Driver Analysis
3.4.1 Increasing Prevalence Of Breast Cancer
3.4.2 Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
3.4.3 Need To Provide Early Diagnosis And Treatment
3.5 Market Restraint Analysis
3.5.1 High Cost Associated With Breast Cancer Liquid Biopsy Tests
3.5.2 Regulatory & Reimbursement Hurdles
3.6 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.7 Porter’s Five Forces Analysis
Chapter 4 Breast Cancer Liquid Biopsy Market - Segment Analysis, By Circulating Biomarkers, 2018 - 2030 (USD Million)
4.1 Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
4.1.1 Circulating Tumor Cells (Ctcs)
4.1.1.1 Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.2 Circulating Cell - Free Dna (Cfdna)
4.1.2.1 Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.3 Extracellular Vesicles (Evs)
4.1.3.1 Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.4 Other Circulating Biomarkers
4.1.4.1 Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5 Breast Cancer Liquid Biopsy Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)
5.1 Breast Cancer Liquid Biopsy Market: Application Movement Analysis
5.1.1 Early Detection/Screening
5.1.1.1 Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2 Diagnosis
5.1.2.1 Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3 Treatment Selection
5.1.3.1 Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.4 Monitoring
5.1.4.1 Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)
According to research report the global liquid biopsy market is projected to reach USD 2,047.9 million by 2022 from USD 715.7 million in 2017, at a CAGR of 23.4%.
The factors driving the growth of this market are the increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy RGet Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350 Cancers in areas such as the bones, brain, pancreas, or other organs were hard to access with liquid biopsy.
These methods permit the analysis of ctDNA, providing physicians with important biomarker information to take effective therapeutic decisions in almost all cancer areas.
The development of technologically advanced liquid biopsy products is aiding the growth of the market.In this report, the market is segmented on the basis of product, circulating biomarker, clinical application, application, end user, and region.
On the basis of product, the global liquid biopsy market is segmented into assays kits, instruments, and services.
It is also the fastest-growing segment in the products market during the forecast period.Based on circulating biomarkers the market is categorised into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers.
The Global Liquid Biopsy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026 gives an evaluation of the market developments based on historical studies and comprehensive research respectively.
The market segments are also provided with an in-depth outlook of the competitive landscape and a listing of the profiled key players.The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved.
The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.The report classifies the market into different segments based on approach of diagnosis, type of cancer application and channel participants.
These segments are studied in detail incorporating the market estimates and forecasts at regional and country level.
The segment analysis is useful in understanding the growth areas and probable opportunities of the market.Final Report will cover the impact of COVID-19 on this industry.Browse the complete Global Liquid Biopsy Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026 @ https://www.decisiondatabases.com/ip/8529-liquid-biopsy-market-reportThe report also covers the complete competitive landscape of the global Liquid Biopsy market with company profiles of key players such as:Janssen Diagnostics, LLCQiagenRarecells SASSilicon BiosystemsSRI InternationalMyriad GeneticsNatera IncPersonal Genome DiagnosticsSysmex InosticsTrovagene Inc.Exosome DiagnosticsExosome SciencesHansaBiomed OUA detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.SEGMENTATIONS IN THE REPORT:By Approach of Diagnosis:Circulating Tumor Cells (CTC)Circulating Tumor DNA (ctDNA)RNA in ExosomesExtra-cellular Vesicles (EVs)By Type of Cancer Application:Lung CancerPancreatic CancerLeukemia (Blood Cancer)Other Visceral (Deeply Located) CancersBy Channel Participants:Cancer Centers and HospitalsContract Research OrganizationsAcademic InstitutionsSpecialized Research LaboratoriesBy Geography:North AmericaEuropeAsia PacificLatin AmericaMiddle East And AfricaDownload Free Sample Report of Global Liquid Biopsy Market @ https://www.decisiondatabases.com/contact/download-sample-8529The Global Liquid Biopsy Market has been exhibited in detail in the following chapters –Chapter 1 Liquid Biopsy Market PrefaceChapter 2 Executive SummaryChapter 3 Liquid Biopsy Industry AnalysisChapter 4 Liquid Biopsy Market Value Chain AnalysisChapter 5 Liquid Biopsy Market Analysis By Approach of DiagnosisChapter 6 Liquid Biopsy Market Analysis By Type of Cancer ApplicationChapter 7 Liquid Biopsy Market Analysis By Channel ParticipantsChapter 8 Liquid Biopsy Market Analysis By GeographyChapter 9 Competitive Landscape Of Liquid Biopsy CompaniesChapter 10 Company Profiles Of Liquid Biopsy IndustryPurchase the complete Global Liquid Biopsy Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-8529Other Reports by DecisionDatabases.com:Global Biopsy Devices Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.
It’s about taking care at the beginning itself and getting cautious to recognize the signs and symptoms of breast cancer, in hopes of catching it early on if it develops.❍ Transformation in a MoleTransformation in a MoleMoles are the sensitive marks that are present right from birth, it is more commonly associated with a higher risk of skin cancer, and they may also be linked to breast cancer.
Researchers claimed this when underwent a study on 89,902 women ages 40-65 years old, over a period of 18 years.
At the beginning of the study, the number of moles each woman had was documented.
If one notices a new mole or any type of change in an existing mole, visit a health care professional immediately.❍ Continuous Cough or Hoarse ThroatContinuous Cough or Hoarse ThroatWhen cancer initiates in one area is known as primary cancer.
If some cancer cells rupture away from primary cancer and move on to another part of the body, they can form another tumor, called secondary cancer.
This is known as incontinence, and common signs include leaking urine during activities such as coughing, laughing, sneezing or exercising, experiencing sudden and urgent needs to urinate, and urination takes a longer time to pass out completely than usual.
